Keyhole limpet haemocyanin - Intracel

Drug Profile

Keyhole limpet haemocyanin - Intracel

Alternative Names: BCI-ImmuneActivator; Keyhole limpet hemocyanin; KLH

Latest Information Update: 20 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intracel Corporation
  • Class Adjuvants; Antineoplastics; Blood proteins; Metalloproteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bladder cancer; Interstitial cystitis

Most Recent Events

  • 22 Feb 2007 No development reported - Phase-III for Bladder cancer in Europe (Intravesicular)
  • 22 Feb 2007 Phase-II clinical trials in Interstitial cystitis (unspecified route)
  • 22 Dec 2003 Mentor has terminated its licence for keyhole limpet haemocyanin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top